APP and Cognitive impairment: The transgenic mice expressing human APP/PSEN1-Tg carrying familial AD mutations used in these studies (B6C3-Tg) have an onset of plaque pathology at around 6 months [47], which is followed by cognitive impairments with both increasing by 12–18 months of age [48].